107 related articles for article (PubMed ID: 35680109)
1. A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer.
Jiang M; Fang X; Ma L; Liu M; Chen M; Liu J; Yang Y; Wang C
Int J Pharm; 2022 Jun; 622():121894. PubMed ID: 35680109
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
[TBL] [Abstract][Full Text] [Related]
4. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
Zhang J; Zeng Y; Xing Y; Li X; Zhou L; Hu L; Chin YE; Wu M
Cancer Lett; 2021 Sep; 516():84-98. PubMed ID: 34102285
[TBL] [Abstract][Full Text] [Related]
5. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
[TBL] [Abstract][Full Text] [Related]
6. MiR-92b inhibits proliferation and invasion of lung cancer by targeting EZH2.
Chen L; Zhuo HZ; Wu JY; Lin LY; Huang ZL; Lu JX; Cheng KL
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3166-3173. PubMed ID: 32271434
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2.
Niu Y; Ma F; Huang W; Fang S; Li M; Wei T; Guo L
Mol Cancer; 2017 Jan; 16(1):5. PubMed ID: 28069000
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5.
Fang X; Xie H; Duan H; Li P; Yousaf M; Xu H; Yang Y; Wang C
PLoS One; 2017; 12(8):e0182697. PubMed ID: 28793338
[TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
10. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
12. EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.
Xia L; Zhu X; Zhang L; Xu Y; Chen G; Luo J
Biotechnol Appl Biochem; 2020 Nov; 67(6):1011-1019. PubMed ID: 31855281
[TBL] [Abstract][Full Text] [Related]
13. α-Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to α7-nAChR overexpressed non-small cell lung cancer.
Mei D; Zhao L; Chen B; Zhang X; Wang X; Yu Z; Ni X; Zhang Q
Drug Deliv; 2018 Nov; 25(1):493-503. PubMed ID: 29426250
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
15. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
16. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway.
Zhang G; Wu YJ; Yan F
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9480-9488. PubMed ID: 31773700
[TBL] [Abstract][Full Text] [Related]
19. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.
Zang X; Gu J; Zhang J; Shi H; Hou S; Xu X; Chen Y; Zhang Y; Mao F; Qian H; Zhu T; Xu W; Zhang X
Cell Death Dis; 2020 Apr; 11(4):215. PubMed ID: 32242003
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor.
Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN
J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
